Roche Holding AG (RHHBF)
| Market Cap | 387.90B +67.3% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | 23.88 |
| Forward PE | n/a |
| Dividend | 12.82 (2.91%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 3 |
| Average Volume | 29 |
| Open | 470.00 |
| Previous Close | 447.50 |
| Day's Range | 440.00 - 470.00 |
| 52-Week Range | 288.90 - 470.38 |
| Beta | 0.17 |
| RSI | 55.14 |
| Earnings Date | Jan 29, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability...
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche Holding AG (RHHBY) Q4 2025 Earnings Call Transcript
Roche Holding AG 2025 Q4 - Results - Earnings Call Presentation
2026-01-29. The following slide deck was published by Roche Holding AG in conjunction with their 2025 Q4 earnings call.
Roche Holding AG (RHHBF) (FY 2025) Earnings Call Highlights: Strong Pharma Growth and Strategic ...
Roche Holding AG (RHHBF) (FY 2025) Earnings Call Highlights: Strong Pharma Growth and Strategic Investments Drive Profit Surge
Full Year 2025 Roche Holding AG Earnings Call Transcript
Full Year 2025 Roche Holding AG Earnings Call Transcript
Roche's Full-Year Earnings: Solid, No Alarms - Obesity Promise Makes The Buy Case
Hoffman-La Roche aka Roche Holding AG delivered robust 2025 results, with core EPS up 11% CER and a resilient pharma division driving growth. RHHBY's pipeline, especially in obesity and cardiovascular...
Roche Sees Steady 2026 Growth As Key Drugs Post Double-Digit Gains
Roche Holdings AG (OTC: RHHBY) reported fiscal 2025 sales of 61.5 billion Swiss Francs (around $76.96 billion), up 7% (+2% in CHF) due to strong demand for pharmaceutical products and diagnostic solu...
How Roche Hopes To Go Toe-To-Toe With Eli Lilly, Novo Nordisk In Obesity
Roche hopes to rival Eli Lilly and Novo Nordisk in the red-hot weight-loss space. The Swiss drug giant is working on four key drugs.
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
Drugmakers Roche and Sanofi posted full-year earnings that matched expectations and did little to move either stock. As pharma companies face a "patent cliff" where existing drugs lose exclusivity, th...
Roche (RHHBY) Faces Currency Challenges Despite Sales Growth
Roche (RHHBY) Faces Currency Challenges Despite Sales Growth
Roche's annual results hit by currency headwinds
Roche's U.S drug prices will be lowered, says CEO
Thomas Schinecker, CEO of Roche discusses the company's weight loss medication pipeline, and explains how the company's pharmaceutical pricing deal with the U.S. administration will impact their finan...
Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline
The Swiss drugmaker said it expects sales to grow in the mid-single-digit range, with core EPS growth in the high-single-digit range at constant currencies.
Roche FY25 Results Climb, Lifts Dividend; Sees Growth In FY26
(RTTNews) - Swiss drug major Roche Holding AG (RHHBY) reported Thursday higher profit and sales in fiscal 2025, mainly with growth in Pharmaceuticals Division sales. The company also announced higher ...
Roche (RHHBY) Reports Strong FY Results and Positive Outlook
Roche (RHHBY) Reports Strong FY Results and Positive Outlook
Roche Holding Non-GAAP EPS of CHF 19.46, revenue of CHF 61.52B; issues FY26 outlook
Roche sees high single-digit earnings growth in 2026
Roche ROG.S said on Thursday it expects 2026 group sales to grow in the mid single-digit percentage range, while targeting core earnings per share growth in the high single-digit range.
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Outlook for 2026 Roche (SIX: RO, ROG; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single ...
Roche's CT-388 Adds Optionality In The GLP Market, But Wait For Dips
Roche Is The 'Value Play' Of The 2026 Obesity Gold Rush
Roche: Important De-Risking Of CT-388 In Obesity, Petrelintide Is Next
Roche's (RHHBY) CT-388 Shows Promising Weight Loss Results in Phase 2 Trial
Roche's (RHHBY) CT-388 Shows Promising Weight Loss Results in Phase 2 Trial
Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss
Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss
Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight
Roche released Phase 2 trial results showing its weekly obesity drug CT-388 helped patients lose up to 22.5% body weight with strong tolerability and no weight loss plateau at 48 ... Full story availa...
Genentech's CT388 Demonstrates Significant 22.5% Weight Loss In Phase 2 Study
(RTTNews) - Genentech, a biotechnology firm and member of the Roche Group (RHHBY,ROG.SW), announced positive topline results from its Phase 2 clinical trial of CT-388 in obesity.